Mr. Pearson sold 288,441 shares on June 30 for $5.8 million, 411,601 shares on July 5 for $8.2 million and just over 4 million shares on July 1 for $82.9 million, according to the report.
The company’s stock prices have plunged more than 90 percent since August 2015, when investigations into Valeant’s drug pricing and financial practices raised significant concerns among regulators.
Valeant moved to replace Mr. Pearson as CEO in March. Under his employment contract, Mr. Pearson is required to hold at least 1 million company shares for two years following his termination.
More articles on finance issues:
OIG tags University of Tennessee Medical Center for incorrect billing
Halifax Regional chooses Vincari’s Lightspeed Valet
50% of physicians have never heard of MACRA, Deloitte finds
Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit
